Apple patent dispute-related work
Establishment of a strategy for testing against patents for genetic scissors
Tulzen announced on the 18th that it had recruited patent attorney Kim Yu-ri and US attorney (photo), a patent expert, as the Chief Legal Officer (CLO).
Patent Attorney Yuri Kim is expected to help diversify Toolgen’s revenue generation through global negotiations to realize the monetization of patents related to CRISPR genetic scissors and establishing strategies related to patent disputes.
Kim CLO passed the 34th patent attorney exam, and then went to the US to pass the US bar exam while serving at a domestic patent firm. He worked as a patent attorney at Silicon Valley’s intellectual property (IP) law firm (Blakely Sokoloff Taylor & Zafman) and Seattle-based Intellectual Ventures, the world’s largest patent monetization company.
After returning to Korea in 2010, he joined Samsung Electronics to establish and implement strategies to respond to various patent issues such as patent disputes with Apple. He is the first woman in the Samsung Electronics patent team to be promoted to managing director. Since 2015, he has operated a specialized IP investment fund worth 100 billion won while working in the venture technology finance office of KDB Development Bank.
The global competition for CRISPR original patents has undergone major changes in recent years, Toolgen said. In December of last year, the US patent of CRISPR gene shear owned by Tulgen, the patents of UC Berkeley and Broad Labs in the United States, began a conflict examination, respectively.
Interference is a procedure for patent registration that was applied in the United States in 2012, when Toolgen applied for the original patent for CRISPR genetic scissors. At the time, the United States adopted a first-inventionist system that establishes the successor relationship of patents based on the actual invention date. If there are two or more applicants claiming the same invention, it is intended to screen the first inventor.
UC Berkeley and Broad Lab, which are considered as leaders in the CRISPR genetic scissors field, are continuing fierce patent competition with two conflicting screenings. It is explained that Toolgen is also competing for patent rights in an equal position with them due to the initiation of conflicting examination.
CLO Kim Yuri said, “In the short term, we will try to achieve good results by responding well to the conflict screenings conducted in the United States.” He said, “I want to help expand into a patent monetization company.”
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution